[{"id":"315599d2-2faa-4fa8-9734-19252ebf4382","acronym":"","url":"https://clinicaltrials.gov/study/NCT01915576","created_at":"2021-01-18T08:38:20.529Z","updated_at":"2025-02-25T17:06:56.587Z","phase":"Phase 1","brief_title":"Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients","source_id_and_acronym":"NCT01915576","lead_sponsor":"Bayer","biomarkers":" AKT1","pipe":" | ","alterations":" AKT1 E17K • AKT1 mutation","tags":["AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AKT1 E17K • AKT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAY 1125976"],"overall_status":"Completed","enrollment":" Enrollment 79","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2016-12-28"}]